{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:56:24Z","timestamp":1783115784566,"version":"3.54.6"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00806-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:15:00Z","timestamp":1755072900000},"page":"2107-2123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Adherence in MS: Does Objective MS Knowledge and MS Risk Knowledge Matter in Relation to Perceived Disease-Modifying Therapy Benefits?"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-2947","authenticated-orcid":false,"given":"Edward","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-7417","authenticated-orcid":false,"given":"Dawn","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"key":"806_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102016","volume":"41","author":"K Stratos","year":"2020","unstructured":"Stratos K, McGarragle K, Thistle J, Vyas MV, Lee L. Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: a qualitative analysis. Mult Scler Relat Disord. 2020;41: 102016. https:\/\/doi.org\/10.1016\/j.msard.2020.102016.","journal-title":"Mult Scler Relat Disord"},{"key":"806_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042203","volume":"19","author":"A Ko\u0142tuniuk","year":"2022","unstructured":"Ko\u0142tuniuk A, Chojdak-\u0141ukasiewicz J. Adherence to therapy in patients with multiple sclerosis. Int J Environ Res Public Health. 2022;19: 2203. https:\/\/doi.org\/10.3390\/ijerph19042203.","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"806_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16790-3","volume":"20","author":"N Giedraitiene","year":"2022","unstructured":"Giedraitiene N, Taluntiene V, Kaubrys G. Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Sci Rep. 2022;20(12): 12447. https:\/\/doi.org\/10.1038\/s41598-022-16790-3.","journal-title":"Sci Rep"},{"key":"806_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104866","volume":"77","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: a claims analysis of real-world data. Mult Scler Relat Disord. 2023;77: 104866. https:\/\/doi.org\/10.1016\/j.msard.2023.104866.","journal-title":"Mult Scler Relat Disord"},{"key":"806_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211028769","author":"MH Rabadi","year":"2021","unstructured":"Rabadi MH, Just K, Xu C. The impact of adherence to disease-modifying therapies on functional outcomes in veterans with multiple sclerosis. J Cent Nerv System Dis. 2021. https:\/\/doi.org\/10.1177\/11795735211028769.","journal-title":"J Cent Nerv System Dis"},{"key":"806_CR7","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.938116","volume":"28","author":"MH Rabadi","year":"2022","unstructured":"Rabadi MH, Just K, Xu C. Impact of adherence with disease-modifying therapies on all-cause mortality rates among veterans with multiple sclerosis. Med Sci Monit. 2022;28: e938116-1. https:\/\/doi.org\/10.12659\/MSM.938116.","journal-title":"Med Sci Monit"},{"key":"806_CR8","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18553\/jmcp.2023.23039","volume":"29","author":"M Schauf","year":"2023","unstructured":"Schauf M, Chinthapatla H, Dimri S, Li E, Hartung DM. Economic burden of multiple sclerosis in the United States: a systematic literature review. J Manag Care Spec Pharm. 2023;29:1354\u201368. https:\/\/doi.org\/10.18553\/jmcp.2023.23039.","journal-title":"J Manag Care Spec Pharm"},{"key":"806_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.36469\/jheor.2022.33288","volume":"9","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Sheinson D, Bonine NG. The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis. J Health Econ Outcomes Res. 2022;9:111\u20136. https:\/\/doi.org\/10.36469\/jheor.2022.33288.","journal-title":"J Health Econ Outcomes Res"},{"key":"806_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101957","volume":"40","author":"G Cutter","year":"2020","unstructured":"Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C. Satisfaction and adherence with glatiramer acetate 40\u00a0mg\/mL TIW in RRMS after 12 months, and the effect of switching from 20\u00a0mg\/mL QD. Mult Scler Relat Disord. 2020;40: 101957. https:\/\/doi.org\/10.1016\/j.msard.2020.101957.","journal-title":"Mult Scler Relat Disord"},{"key":"806_CR11","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.2147\/PPA.S424024","volume":"17","author":"K King","year":"2023","unstructured":"King K, McGuinness S, Watson N, Norton C, Chalder T, Czuber-Dochan W. What do we know about medication adherence interventions in inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis? A scoping review of randomised controlled trials. Patient Prefer Adherence. 2023;17:3265\u2013303. https:\/\/doi.org\/10.2147\/PPA.S424024.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.23430","author":"AR Cappola","year":"2024","unstructured":"Cappola AR, Cohen KS. Strategies to improve medical communication. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2023.23430.","journal-title":"JAMA"},{"key":"806_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00005650-197501000-00002","volume":"13","author":"MH Becker","year":"1975","unstructured":"Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care. 1975;13:10\u201324.","journal-title":"Med Care"},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1177\/1352458507078911","volume":"13","author":"AP Turner","year":"2007","unstructured":"Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler J. 2007;13:1146\u201352. https:\/\/doi.org\/10.1177\/1352458507078911.","journal-title":"Mult Scler J"},{"key":"806_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:1\u201313. https:\/\/doi.org\/10.1186\/1477-7525-2-12.","journal-title":"Health Qual Life Outcomes"},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/1352458516657441","volume":"23","author":"P Vermersch","year":"2017","unstructured":"Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK. Measuring treatment satisfaction in MS: is the Treatment Satisfaction Questionnaire for Medication fit for purpose? Mult Scler J. 2017;23:604\u201313. https:\/\/doi.org\/10.1177\/1352458516657441.","journal-title":"Mult Scler J"},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.nrl.2013.12.008","volume":"30","author":"A Saiz","year":"2015","unstructured":"Saiz A, Mora S, Blanco J. Cumplimiento terap\u00e9utico con terapias modificadoras de la enfermedad de primera l\u00ednea en pacientes con esclerosis m\u00faltiple. Estudio Compliance Neurolog\u00eda. 2015;30:214\u201322. https:\/\/doi.org\/10.1016\/j.nrl.2013.12.008.","journal-title":"Estudio Compliance Neurolog\u00eda"},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/175628561663424","volume":"9","author":"R Haase","year":"2016","unstructured":"Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing\u2013remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9:250\u201363. https:\/\/doi.org\/10.1177\/175628561663424.","journal-title":"Ther Adv Neurol Disord"},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3855\/jidc.9653","volume":"12","author":"N Azizi","year":"2018","unstructured":"Azizi N, Karimy M, Salahshour VN. Determinants of adherence to tuberculosis treatment in Iranian patients: Application of health belief model. J Infect Dev Ctries. 2018;12:706\u201311. https:\/\/doi.org\/10.3855\/jidc.9653.","journal-title":"J Infect Dev Ctries"},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.pec.2015.02.007","volume":"98","author":"Z Yue","year":"2015","unstructured":"Yue Z, Li C, Weilin Q, Bin W. Application of the health belief model to improve the understanding of antihypertensive medication adherence among Chinese patients. Patient Educ Couns. 2015;98:669\u201373. https:\/\/doi.org\/10.1016\/j.pec.2015.02.007.","journal-title":"Patient Educ Couns"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.47391\/JPMA.1463","volume":"71","author":"M Ashraf","year":"2021","unstructured":"Ashraf M, Virk RN. Determinants of medication adherence in patients with HIV: 3 application of the Health Belief Model 4. JPMA. 2021;71:1409\u201312. https:\/\/doi.org\/10.47391\/JPMA.1463.","journal-title":"JPMA"},{"key":"806_CR22","unstructured":"Harding K, Horne R. Compliance, adherence and concordance. In Pharmacy practice. London: Taylor & Francis; 2001. pp. 148\u201369."},{"key":"806_CR23","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1007\/s10461-022-03624-6","volume":"26","author":"D Arnold-Forster","year":"2022","unstructured":"Arnold-Forster D, Horne R, Nutland W, Wayal S, Rayment M, Rae C, Desai M, Clarke A, Sullivan A, McCormack S. Perceptions and practicalities influencing pre-exposure prophylaxis adherence among men who have sex with men in England. AIDS Behav. 2022;26:2768\u201382. https:\/\/doi.org\/10.1007\/s10461-022-03624-6.","journal-title":"AIDS Behav"},{"key":"806_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.13097","volume":"56","author":"SC Chapman","year":"2015","unstructured":"Chapman SC, Horne R, Eade R, Balestrini S, Rush J, Sisodiya SM. Applying a perceptions and practicalities approach to understanding nonadherence to antiepileptic drugs. Epilepsia. 2015;56:1398\u2013407. https:\/\/doi.org\/10.1111\/epi.13097.","journal-title":"Epilepsia"},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.7224\/1537-2073.2022-018","volume":"25","author":"E Neter","year":"2023","unstructured":"Neter E, Miller A. Using an intervention mapping approach to improve adherence to disease-modifying treatment in multiple sclerosis. Int J MS Care. 2023;25:206\u201313. https:\/\/doi.org\/10.7224\/1537-2073.2022-018.","journal-title":"Int J MS Care"},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/1352458509352865","volume":"16","author":"A Giordano","year":"2010","unstructured":"Giordano A, Messmer Uccelli M, Pucci E, Martinelli V, Borreani C, Lugaresi A, Trojano M, Granella F, Confalonieri P, Radice D. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Mult Scler J. 2010;16:100\u201311. https:\/\/doi.org\/10.1177\/1352458509352865.","journal-title":"Mult Scler J"},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jns.2013.02.018","volume":"331","author":"C Heesen","year":"2013","unstructured":"Heesen C, K\u00f6pke S, Solari A, Geiger F, Kasper J. Patient autonomy in multiple sclerosis\u2014possible goals and assessment strategies. J Neurol Sci. 2013;331:2\u20139. https:\/\/doi.org\/10.1016\/j.jns.2013.02.018.","journal-title":"J Neurol Sci"},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2017.09.020","volume":"18","author":"C Heesen","year":"2017","unstructured":"Heesen C, P\u00f6ttgen J, Rahn AC, Liethmann K, Kasper J, Vahter L, Drulovic J, Van Nunen A, Wilkie D, Beckmann Y. What should a person with relapsing-remitting multiple sclerosis know? Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0). Mult Scler Relat Disord. 2017;18:186\u201395. https:\/\/doi.org\/10.1016\/j.msard.2017.09.020.","journal-title":"Mult Scler Relat Disord"},{"key":"806_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1037\/hea0000626","volume":"37","author":"JM Bruce","year":"2018","unstructured":"Bruce JM, Jarmolowicz DP, Lynch S, Thelen J, Lim S, Smith J, Catley D, Bruce AS. How patients with multiple sclerosis weigh treatment risks and benefits. Health Psychol. 2018;37:680\u201390. https:\/\/doi.org\/10.1037\/hea0000626.","journal-title":"Health Psychol"},{"key":"806_CR30","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1007\/s00213-018-5037-y","volume":"235","author":"JM Bruce","year":"2018","unstructured":"Bruce JM, Bruce AS, Lynch S, Thelen J, Lim S, Smith J, Catley D, Reed DD, Jarmolowicz DP. Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. Psychopharmacology. 2018;235:3303\u201313. https:\/\/doi.org\/10.1007\/s00213-018-5037-y.","journal-title":"Psychopharmacology"},{"key":"806_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2016.12.038","volume":"375","author":"GK Reen","year":"2017","unstructured":"Reen GK, Silber E, Langdon DW. Multiple sclerosis patients\u2019 understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107\u201322. https:\/\/doi.org\/10.1016\/j.jns.2016.12.038.","journal-title":"J Neurol Sci"},{"key":"806_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/135245859600200502","volume":"2","author":"DC Mohr","year":"1996","unstructured":"Mohr DC, Goodkin DE, Likosk W, Gatto N, Neilley LK, Griffin C, Stiebling B. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: relationship to adherence to treatment. Mult Scler J. 1996;2:222\u20136. https:\/\/doi.org\/10.1177\/135245859600200502.","journal-title":"Mult Scler J"},{"key":"806_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1037\/1040-3590.5.1.102","volume":"5","author":"MR DiMatteo","year":"1993","unstructured":"DiMatteo MR, Hays RD, Gritz ER, Bastani R, Crane L, Elashoff R, Ganz P, Heber D, McCarthy W, Marcus A. Patient adherence to cancer control regimens: scale development and initial validation. Psychol Assess. 1993;5:102\u201312. https:\/\/doi.org\/10.1037\/1040-3590.5.1.102.","journal-title":"Psychol Assess"},{"key":"806_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1212\/WNL.45.2.251","volume":"45","author":"MJ Hohol","year":"1995","unstructured":"Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251\u20135. https:\/\/doi.org\/10.1212\/WNL.45.2.251.","journal-title":"Neurology"},{"key":"806_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF00844941","volume":"15","author":"CD Sherbourne","year":"1992","unstructured":"Sherbourne CD, Hays RD, Ordway L, DiMatteo MR, Kravitz RL. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med. 1992;15:447\u201368. https:\/\/doi.org\/10.1007\/BF00844941.","journal-title":"J Behav Med"},{"key":"806_CR36","unstructured":"British Psychological Society. Code of human research ethics. Br Psychol Soc; 2014."},{"key":"806_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.34172\/jcs.2021.015","volume":"10","author":"H Habibi","year":"2021","unstructured":"Habibi H, Sedighi B, Jahani Y, Hasani M, Iranpour A. Self-care practices and related factors in patients with multiple sclerosis (MS) based on the Health Belief Model. J Caring Sci. 2021;10:77\u201383. https:\/\/doi.org\/10.34172\/jcs.2021.015.","journal-title":"J Caring Sci"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.2147\/PPA.S375062","volume":"16","author":"HE Masri","year":"2022","unstructured":"Masri HE, McGuire TM, van Driel ML, Benham H, Hollingworth SA. Dynamics of patient-based benefit-risk assessment of medicines in chronic diseases: a systematic review. Patient Prefer Adherence. 2022;16:2609\u201337. https:\/\/doi.org\/10.2147\/PPA.S375062.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17437199.2016.1240624","volume":"11","author":"BM Rottman","year":"2017","unstructured":"Rottman BM, Marcum ZA, Thorpe CT, Gellad WF. Medication adherence as a learning process: insights from cognitive psychology. Health Psychol Rev. 2017;11:17\u201332. https:\/\/doi.org\/10.1080\/17437199.2016.1240624.","journal-title":"Health Psychol Rev"},{"key":"806_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1037\/pha0000322","volume":"28","author":"DP Jarmolowicz","year":"2020","unstructured":"Jarmolowicz DP, Reed DD, Schneider TD, Smith J, Thelen J, Lynch S, Bruce AS, Bruce JM. Behavioral economic demand for medications and its relation to clinical measures in multiple sclerosis. Exp Clin Psychopharmacol. 2020;28:258\u201364.","journal-title":"Exp Clin Psychopharmacol"},{"key":"806_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2022.05.020","volume":"149","author":"M Gonzalez-del-Rio","year":"2022","unstructured":"Gonzalez-del-Rio M, Bertran-Noguer C, Rami\u00f3-Torrent\u00e0 L, Zabaleta-del-Olmo E. Multiple sclerosis disease-related knowledge measurement instruments show mixed performance: a systematic review. J Clin Epidemiol. 2022;149:60\u201382. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.05.020.","journal-title":"J Clin Epidemiol"},{"key":"806_CR42","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2147\/PPA.S418246","volume":"17","author":"Q Pan","year":"2023","unstructured":"Pan Q, Zhang C, Yao L, Mai C, Zhang J, Zhang Z, Hu J. Factors influencing medication adherence in elderly patients with hypertension: a single center study in western China. Patient Prefer Adherence. 2023;17:1679\u201388. https:\/\/doi.org\/10.2147\/PPA.S418246.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/PPA.S412136","volume":"1","author":"V Poletti","year":"2023","unstructured":"Poletti V, Pagnini F, Banfi P, Volpato E. Illness perceptions, cognitions, and beliefs on COPD patients\u2019 adherence to treatment\u2014a systematic review. Patient Prefer Adherence. 2023;1:845\u20131866. https:\/\/doi.org\/10.2147\/PPA.S412136.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.sapharm.2023.04.116","volume":"19","author":"Y Mo","year":"2023","unstructured":"Mo Y, Park HS. Message frame and health literacy: strategies to improve adherence to antihypertensive medications. Res Soc Admin Pharm. 2023;19:1042\u20137. https:\/\/doi.org\/10.1016\/j.sapharm.2023.04.116.","journal-title":"Res Soc Admin Pharm"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"1124297","DOI":"10.3389\/fphar.2023.1124297","volume":"14","author":"S Yoon","year":"2023","unstructured":"Yoon S, Kwan YH, Yap WL, Lim ZY, Phang JK, Loo YX, Aw J, Low LL. Factors influencing medication adherence in multi-ethnic Asian patients with chronic diseases in Singapore: a qualitative study. Front Pharmacol. 2023;14:1124297. https:\/\/doi.org\/10.3389\/fphar.2023.1124297.","journal-title":"Front Pharmacol"},{"key":"806_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","volume":"50","author":"I Ajzen","year":"1991","unstructured":"Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179\u2013211.","journal-title":"Organ Behav Hum Decis Process"},{"key":"806_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1037\/0022-006X.51.3.390","volume":"51","author":"JO Prochaska","year":"1983","unstructured":"Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390. https:\/\/doi.org\/10.1037\/0022-006X.51.3.390.","journal-title":"J Consult Clin Psychol"},{"key":"806_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/10410236.2010.521906","volume":"25","author":"CJ Carpenter","year":"2010","unstructured":"Carpenter CJ. A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Commun. 2010;25:661\u20139. https:\/\/doi.org\/10.1080\/10410236.2010.521906.","journal-title":"Health Commun"},{"key":"806_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12160-017-9895-z","volume":"51","author":"DP French","year":"2017","unstructured":"French DP, Cameron E, Benton JS, Deaton C, Harvie M. Can communicating personalised disease risk promote healthy behaviour change? A systematic review of systematic reviews. Ann Behav Med. 2017;51:718\u201329. https:\/\/doi.org\/10.1007\/s12160-017-9895-z.","journal-title":"Ann Behav Med"},{"key":"806_CR50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/heapro\/daq050","volume":"26","author":"T Van Achterberg","year":"2011","unstructured":"Van Achterberg T, Huisman-de Waal GG, Ketelaar NA, Oostendorp RA, Jacobs JE, Wollersheim HC. How to promote healthy behaviours in patients? An overview of evidence for behaviour change techniques. Health Promot Int. 2011;26:148\u201362. https:\/\/doi.org\/10.1093\/heapro\/daq050.","journal-title":"Health Promot Int"},{"key":"806_CR51","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.2466","volume":"15","author":"RA Marrie","year":"2013","unstructured":"Marrie RA, Salter AR, Tyry T, Fox RJ, Cutter GR. Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought. J Med Internet Res. 2013;15: e2466. https:\/\/doi.org\/10.2196\/jmir.2466.","journal-title":"J Med Internet Res"},{"key":"806_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102702","volume":"48","author":"R Alonso","year":"2021","unstructured":"Alonso R, Carvajal R, Boaventura M, Galleguillos L. Experience of South American MS and\/or NMOSD experts in practice during the COVID-19 pandemic: focus on telemedicine. Mult Scler Relat Disord. 2021;48: 102702. https:\/\/doi.org\/10.1016\/j.msard.2020.102702.","journal-title":"Mult Scler Relat Disord"},{"key":"806_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16046","volume":"31","author":"YC Foong","year":"2024","unstructured":"Foong YC, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, Barnett M, Taylor B, Kalincik T, Kilpatrick T. The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis. Eur J Neurol. 2024;31: e16046. https:\/\/doi.org\/10.1111\/ene.16046.","journal-title":"Eur J Neurol"},{"key":"806_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7224\/1537-2073.2021-102","volume":"25","author":"R Ann Marrie","year":"2023","unstructured":"Ann Marrie R, McFadyen C, Yaeger L, Salter A. A systematic review of the validity and reliability of the patient-determined disease steps scale. Int J MS Care. 2023;25:20\u20135. https:\/\/doi.org\/10.7224\/1537-2073.2021-102.","journal-title":"Int J MS Care"},{"key":"806_CR55","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1017\/cjn.2022.131","volume":"49","author":"S Ballendine","year":"2022","unstructured":"Ballendine S, Poliakov I. P.029 Assessing disability in MS during the COVID-19 pandemic: correlation between PDDS and EDSS scores obtained before and after virtual assessments. Can J Neurol Sci. 2022;49:S15. https:\/\/doi.org\/10.1017\/cjn.2022.131.","journal-title":"Can J Neurol Sci"},{"key":"806_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294116","volume":"19","author":"M Jo\u017eef","year":"2024","unstructured":"Jo\u017eef M, Locatelli I, Brecl Jakob G, Sav\u0161ek L, \u0160urlan Popovi\u010d K, \u0160piclin \u017d, Rot U, Kos M. Psychometric evaluation of the 5-item Medication Adherence Report Scale questionnaire in persons with multiple sclerosis. PLoS\u00a0One. 2024;19: e0294116. https:\/\/doi.org\/10.1371\/journal.pone.0294116.","journal-title":"PLoS\u00a0One"},{"key":"806_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","volume":"2015","author":"WY Lam","year":"2015","unstructured":"Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015;2015: 217047. https:\/\/doi.org\/10.1155\/2015\/217047.","journal-title":"BioMed Res Int"},{"key":"806_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16289","volume":"31","author":"EC Tallantyre","year":"2024","unstructured":"Tallantyre EC, Dobson R, Froud JL, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I. Real-world persistence of multiple sclerosis disease-modifying therapies. Eur J Neurol. 2024;31: e16289. https:\/\/doi.org\/10.1111\/ene.16289.","journal-title":"Eur J Neurol"},{"key":"806_CR59","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","volume":"269","author":"F Washington","year":"2022","unstructured":"Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269:1861\u201372. https:\/\/doi.org\/10.1007\/s00415-021-10850-w.","journal-title":"J Neurol"},{"key":"806_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/PPA.S452849","volume":"18","author":"O Hoffmann","year":"2024","unstructured":"Hoffmann O, Paul F, Haase R, Kern R, Ziemssen T. Preferences, adherence, and satisfaction: three years of treatment experiences of people with multiple sclerosis. Patient Prefer Adherence. 2024;18:455\u201366. https:\/\/doi.org\/10.2147\/PPA.S452849.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR61","doi-asserted-by":"publisher","first-page":"639","DOI":"10.18553\/jmcp.2021.20413","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data. J Manag Care Spec Pharm. 2021;27:639\u201349. https:\/\/doi.org\/10.18553\/jmcp.2021.20413.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:37Z","timestamp":1758367357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00806-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Edward Smith declares no conflict of interest. Dawn Langdon has received grants, consultancy and speaker bureau honoraria from Bayer, Novartis, Merck, Roche, TEVA, Sanofi, Celgene, BMS and Biogen. Dawn Langdon is an Editorial Board member of Neurology and Therapy. Dawn Langdon was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in line with The Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964). Ethical approval for the study was granted by the Royal Holloway University Research Ethics Committee (Research Ethics Committee Project ID: 2532). Implied informed consent for participation and data publication were obtained. This was in accordance with guidelines stipulated in the British Psychological Society\u2019s Code of Human Research Ethics [] concerning studies obtaining anonymised-at-source non-sensitive data and underwent ethical review and approval prior to the study. Participants were aware their responses were for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}